Loading
Immune Cells in Cancer / Cancer Research and Treatments · Journal article
Nature Nanotechnology · August 10, 2026
Encouraging direction, but not yet definitive.
This is a preclinical mechanistic study that identified 3,4-dihydroxybenzoic acid as a gut microbial metabolite capable of enhancing CD8+ T cell stemness via suppression of glycolysis and Akt-mTORC1-Myc pathway inhibition. An oral nano-emulsion formulation of this metabolite demonstrated improved absorption and half-life, and sensitized multiple murine tumour models to anti-PD-1 blockade with robust antitumour efficacy. The work establishes a potential mechanistic link between gut microbiota and T cell immunity but remains preclinical and requires clinical translation.
In vitro screening and preclinical in vivo murine tumour model study. In vitro: CD8+ T cells (source not specified); In vivo: murine tumour models (specific strains, tumour types, and animal numbers not stated). Intervention: Oral nano-emulsion of 3,4-dihydroxybenzoic acid prodrug formulation, with or without anti-PD-1 blockade. Compared with: Anti-PD-1 blockade alone (implied by 'sensitizing tumours to anti-PD-1 blockade'; explicit comparator arms not detailed in abstract).
3,4-dihydroxybenzoic acid improved adoptive T cell therapy and enhanced CD8+ T cell stemness by suppressing glycolysis and regulating Akt-mTORC1-Myc pathway in vitro Oral nano-emulsion significantly increased 3,4-dihydroxybenzoic acid oral absorption and half-life Oral nano-emulsion enhanced expansion of antigen-specific, stem-like CD8+ T cells in multiple murine tumour models
Formulation details, dosing regimens, toxicology, and pharmacokinetic parameters in mice not specified in abstract.
This preclinical work may inform future immunotherapy approaches combining gut microbial metabolites with checkpoint inhibitors, but substantial development and clinical validation will be required before application to human patients. The mechanistic insights into T cell metabolism regulation offer a rationale for further drug development but do not yet constitute evidence for clinical practice.
A mechanistic study with in vitro screening and murine tumour models showing enhanced anti-tumour efficacy in combination with anti-PD-1, but no clinical data or human trials reported.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical work may inform future immunotherapy approaches combining gut microbial metabolites with checkpoint inhibitors, but substantial development and clinical validation will be required before application to human patients. The mechanistic insights into T cell metabolism regulation offer a rationale for further drug development but do not yet constitute evidence for clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Gut microbial metabolites play crucial roles in regulating systemic immunity, but their mechanisms and limited drug-like properties remain unresolved. Here we report an oral nano-formulation that leverages gut microbial metabolites to modulate T cell metabolism and amplify antitumour immunity. Through an in vitro screening of gut microbial metabolites, we identified 3,4-dihydroxybenzoic acid that improved adoptive T cell therapy and enhanced CD8+ T cell stemness by suppressing glycolysis and regulating the Akt-mTORC1-Myc pathway. To harness the potency of 3,4-dihydroxybenzoic acid for systemic cancer immunotherapy, we engineered a 3,4-dihydroxybenzoic acid prodrug nano-emulsion, significantly increasing its oral absorption and half-life. In multiple murine tumour models, the oral nano-emulsion enhanced the expansion of antigen-specific, stem-like CD8+ T cells, sensitizing tumours to anti-PD-1 blockade and exerting robust antitumour efficacy. By integrating nanotechnology with microbial-metabolite-based immunotherapy, this study establishes a mechanistic link between the gut microbiota and T cell immunity, offering a promising approach for cancer immunotherapy. A nano-emulsion that delivers the gut microbial metabolite 3,4-dihydroxybenzoic acid in a prodrug form enhances T cell stemness and boosts the efficacy of immunotherapy approaches in different murine cancer models.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.